Presence and elimination of the xenoantigen gal (alpha1, 3) gal in tissue-engineered heart valves.

Tissue engineering of heart valves promises to create functional autologous tissue with the potential for regeneration and growth without the limitations of current heart valve prostheses. The appropriate valve matrix is essential. Porcine heart valves are attractive because of their anatomical similarity. Decellularization is used for antigen reduction. The efficacy of published protocols varies, however. The absence of a specific immunological or unspecific inflammatory reaction is mandatory. The porcine cell-specific alpha-Gal epitope is known to be responsible for hyperacute rejection in xenotransplantation. In tissue engineering residual alpha-Gal epitope may induce severe inflammation in humans and may lead to graft failure. In this study porcine pulmonary conduits were decellularized with Triton X-100, sodium deoxycholate, Igepal CA-630, and ribonuclease treatment and were compared with specimens of the commercially available porcine decellularized SynerGraft regarding cell removal and elimination of the alpha-Gal epitope. In addition, samples of a porcine bioprosthesis were examined for the presence of the alpha-Gal epitope. In conclusion, we describe for the first time the presence of the alpha-Gal epitope in clinically used porcine bioprostheses and the first generation of a commercial tissue-engineered heart valve. In contrast, complete cell and alpha-Gal removal was achieved by a decellularization procedure developed by our group.

[1]  E Wolner,et al.  Early failure of the tissue engineered porcine heart valve SYNERGRAFT in pediatric patients. , 2003, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[2]  E Wolner,et al.  Comparison of Different Decellularization Procedures of Porcine Heart Valves , 2003, The International journal of artificial organs.

[3]  D. Adams,et al.  Mechanisms of Galα1-3Galβ1-4GlcNAc-R (αGal) expression on porcine valve endothelial cells , 2003 .

[4]  H. Mertsching,et al.  Construction of Autologous Human Heart Valves Based on an Acellular Allograft Matrix , 2002, Circulation.

[5]  W. Kim,et al.  Tissue-Engineered Heart Valve Leaflets: An Effective Method of Obtaining Acellularized Valve Xenografts , 2002, The International journal of artificial organs.

[6]  B J Messmer,et al.  Fibrin gel -- advantages of a new scaffold in cardiovascular tissue engineering. , 2001, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[7]  A Haverich,et al.  Tissue Engineering of Pulmonary Heart Valves on Allogenic Acellular Matrix Conduits: In Vivo Restoration of Valve Tissue , 2000, Circulation.

[8]  Frederick J. Schoen,et al.  Early In Vivo Experience With Tissue-Engineered Trileaflet Heart Valves , 2000, Circulation.

[9]  R. Mitchell,et al.  Fresh porcine cardiac valves are not rejected in primates. , 2000, The Journal of thoracic and cardiovascular surgery.

[10]  W. Chitwood,et al.  Video-assisted and robotic mitral valve surgery: toward an endoscopic surgery. , 1999, Seminars in thoracic and cardiovascular surgery.

[11]  U. Galili,et al.  Porcine and bovine cartilage transplants in cynomolgus monkey: I. A model for chronic xenograft rejection. , 1997, Transplantation.

[12]  U. Galili,et al.  Porcine and bovine cartilage transplants in cynomolgus monkey: II. Changes in anti-Gal response during chronic rejection. , 1997, Transplantation.

[13]  D. Ross,et al.  Factors in the early failure of cryopreserved homograft pulmonary valves in children: preserved immunogenicity? , 1996, The Journal of thoracic and cardiovascular surgery.

[14]  P E Oyer,et al.  Twenty-year clinical experience with porcine bioprostheses. , 1996, The Annals of thoracic surgery.

[15]  Richard A. Lange,et al.  Prosthetic heart valves. , 1996, The New England journal of medicine.

[16]  J. Girardot,et al.  Role of glutaraldehyde in calcification of porcine heart valves: comparing cusp and wall. , 1995, Journal of biomedical materials research.

[17]  M. Breimer,et al.  Natural Antibodies and Human Xenotransplantation , 1994, Immunological reviews.

[18]  M. Sandrin,et al.  Galα(1,3)Gal, the Major Xenoantigen(s) Recognised in Pigs by Human Natural Antibodies , 1994, Immunological reviews.

[19]  R. Oriol,et al.  Oligosaccharides and Discordant Xenotransplantation , 1994, Immunological reviews.

[20]  A Starr,et al.  Actuarial versus actual risk of porcine structural valve deterioration. , 1994, The Journal of thoracic and cardiovascular surgery.

[21]  F. R. Rosendaal,et al.  Thromboembolic and Bleeding Complications in Patients With Mechanical Heart Valve Prostheses , 1994, Circulation.

[22]  W G Henderson,et al.  A comparison of outcomes in men 11 years after heart-valve replacement with a mechanical valve or bioprosthesis. Veterans Affairs Cooperative Study on Valvular Heart Disease. , 1993, The New England journal of medicine.

[23]  W. E. Jamieson,et al.  Modern Cardiac Valve Devices— Bioprostheses and Mechanical Prostheses: State of the Art , 1993, Journal of cardiac surgery.

[24]  F J Schoen,et al.  Bioprosthetic heart valve failure: pathology and pathogenesis. , 1984, Cardiology clinics.

[25]  M. Thubrikar,et al.  Role of mechanical stress in calcification of aortic bioprosthetic valves. , 1983, The Journal of thoracic and cardiovascular surgery.

[26]  F. Bach.  Xenotransplantation: problems and prospects. , 1998, Annual review of medicine.